Additional metal ions

Additional metal ions is a non-specific, categorical term used to describe a variety of metallic elements—including gold, ruthenium, copper, gallium, and manganese—that function as therapeutic agents or essential biochemical cofactors (Frontiers in Pharmacology, 2023). In the context of oncology, these ions are often incorporated into metallodrugs designed to overcome resistance to traditional platinum-based therapies by targeting DNA, inhibiting enzymes like thioredoxin reductase, or inducing oxidative stress (Frontiers in Pharmacology, 2023). Furthermore, in the field of metalloimmunotherapy, ions such as manganese (Mn2+) are utilized to activate the cGAS-STING pathway, thereby enhancing the host's innate immune response against tumors (Nature Biomedical Engineering, 2024). In structural biology, the term may also refer to auxiliary metal ions that bind to secondary protein sites to modulate structural stability or catalytic activity (UniProt, 2024). Because it encompasses a broad range of elements with distinct biological roles, the term is considered a generic classification rather than a specific, singular therapeutic target (Nature Biomedical Engineering, 2024). Clinical applications of these ions are frequently limited by challenges such as systemic toxicity, poor selectivity, and the risk of bioaccumulation (Frontiers in Pharmacology, 2023). Despite these hurdles, research continues into their potential as metalloimmunotherapies and as tools for fine-tuning recombinant protein production in bioprocessing (Nature Biomedical Engineering, 2024; US Patent 9598667B2).

Other names

Other metal ionsNon-platinum metal ionsMetallodrug componentsTrace metal cofactorsMetalloimmunotherapy agents

Drugs involving these ions typically act through DNA adduct formation, inhibition of redox-active enzymes like thioredoxin reductase, generation of reactive oxygen species (ROS), or activation of immune signaling pathways such as cGAS-STING (Frontiers in Pharmacology, 2023; Nature Biomedical Engineering, 2024).